Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -161.05% | 193.31% | -175.44% | 566.36% | -94.38% |
| Total Depreciation and Amortization | 0.08% | -0.41% | 38.72% | 11.42% | 11.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 281.36% | 275.66% | -107.72% | -19.21% | 48.36% |
| Change in Net Operating Assets | -150.00% | -6.30% | -52.16% | -16.30% | -35.15% |
| Cash from Operations | -14.85% | 72.19% | -66.08% | -2.12% | -16.33% |
| Capital Expenditure | 94.40% | -135.85% | 13.11% | -64.86% | -15.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -346.61% | 81.64% | -436.00% | 15.73% | 0.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | 98.28% | -- |
| Cash from Investing | 29.30% | -13.48% | -330.69% | 83.94% | -525.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 92.56% | -363.27% | 0.06% | 19.27% | -23.88% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 40.19% | 5.13% | 29.31% | 12.05% | -10.30% |
| Cash from Financing | 90.18% | -207.42% | 439.97% | 17.60% | -20.44% |
| Foreign Exchange rate Adjustments | -147.22% | -52.94% | 150.66% | -603.33% | 372.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.33% | -194.26% | 958.04% | 199.12% | -146.30% |